Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
Kane Biotech (KNBIF) has secured a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel product line. This strategic partnership follows Health Canada's approval of revyve™ in November 2024, marking a significant expansion in the Canadian healthcare market.
The company has been actively promoting the product's integration into Canadian healthcare systems through strategic partnerships, educational initiatives, and healthcare professional engagement. The distribution agreement aims to enhance accessibility of wound care solutions across hospitals, clinics, and long-term care facilities throughout Canada.
Kane Biotech's President & CEO Marc Edwards highlighted the partnership's dual benefit of improving access to innovative wound care solutions while capitalizing on significant financial opportunities in the Canadian wound care market.
Kane Biotech (KNBIF) ha siglato un accordo di distribuzione triennale con Best Buy Medical Canada per la sua linea di prodotti revyve™ Antimicrobial Wound Gel. Questa partnership strategica segue l'approvazione di revyve™ da parte di Health Canada nel novembre 2024, segnando una significativa espansione nel mercato sanitario canadese.
L'azienda ha attivamente promosso l'integrazione del prodotto nei sistemi sanitari canadesi attraverso partnership strategiche, iniziative educative e coinvolgimento dei professionisti della salute. L'accordo di distribuzione mira a migliorare l'accessibilità delle soluzioni per la cura delle ferite in ospedali, cliniche e strutture di assistenza a lungo termine in tutto il Canada.
Il Presidente e CEO di Kane Biotech, Marc Edwards, ha evidenziato il doppio beneficio della partnership: migliorare l'accesso a soluzioni innovative per la cura delle ferite, sfruttando al contempo significative opportunità finanziarie nel mercato canadese della cura delle ferite.
Kane Biotech (KNBIF) ha firmado un acuerdo de distribución por tres años con Best Buy Medical Canada para su línea de productos revyve™ Antimicrobial Wound Gel. Esta asociación estratégica sigue a la aprobación de revyve™ por parte de Health Canada en noviembre de 2024, marcando una expansión significativa en el mercado de la salud canadiense.
La empresa ha estado promoviendo activamente la integración del producto en los sistemas de salud canadienses a través de asociaciones estratégicas, iniciativas educativas y el compromiso de los profesionales de la salud. El acuerdo de distribución tiene como objetivo mejorar la accesibilidad de las soluciones para el cuidado de heridas en hospitales, clínicas y centros de atención a largo plazo en todo Canadá.
El presidente y CEO de Kane Biotech, Marc Edwards, destacó el doble beneficio de la asociación: mejorar el acceso a soluciones innovadoras para el cuidado de heridas mientras se aprovechan las significativas oportunidades financieras en el mercado canadiense del cuidado de heridas.
케인 바이오텍 (KNBIF)는 베스트 바이 의료 캐나다와 revyve™ 항균 상처 젤 제품 라인에 대한 3년 배급 계약을 체결했습니다. 이 전략적 파트너십은 2024년 11월 캐나다 보건부의 revyve™ 승인에 이어 캐나다 의료 시장에서의 중요한 확장을 의미합니다.
회사는 전략적 파트너십, 교육 이니셔티브 및 의료 전문가의 참여를 통해 제품의 캐나다 의료 시스템 통합을 적극적으로 촉진하고 있습니다. 배급 계약은 캐나다 전역의 병원, 클리닉 및 장기 요양 시설에서 상처 치료 솔루션의 접근성을 향상시키는 것을 목표로 하고 있습니다.
케인 바이오텍의 회장 겸 CEO인 마크 에드워즈는 파트너십의 이중 이점, 즉 혁신적인 상처 치료 솔루션에 대한 접근성을 개선하면서 캐나다 상처 치료 시장에서의 중요한 재정적 기회를 활용할 수 있다고 강조했습니다.
Kane Biotech (KNBIF) a signé un accord de distribution de trois ans avec Best Buy Medical Canada pour sa gamme de produits revyve™ Antimicrobial Wound Gel. Ce partenariat stratégique fait suite à l'approbation de revyve™ par Santé Canada en novembre 2024, marquant une expansion significative sur le marché de la santé canadien.
L'entreprise a activement promu l'intégration du produit dans les systèmes de santé canadiens grâce à des partenariats stratégiques, des initiatives éducatives et l'engagement des professionnels de la santé. L'accord de distribution vise à améliorer l'accessibilité des solutions de soins des plaies dans les hôpitaux, les cliniques et les établissements de soins de longue durée à travers le Canada.
Le président et CEO de Kane Biotech, Marc Edwards, a souligné le double avantage de ce partenariat : améliorer l'accès à des solutions innovantes de soins des plaies tout en capitalisant sur d'importantes opportunités financières sur le marché canadien des soins des plaies.
Kane Biotech (KNBIF) hat einen dreijährigen Vertriebsvertrag mit Best Buy Medical Canada für seine Produktlinie revyve™ Antimicrobial Wound Gel abgeschlossen. Diese strategische Partnerschaft folgt auf die Genehmigung von revyve™ durch Health Canada im November 2024 und stellt eine bedeutende Expansion im kanadischen Gesundheitsmarkt dar.
Das Unternehmen hat aktiv die Integration des Produkts in die kanadischen Gesundheitssysteme durch strategische Partnerschaften, Bildungsinitiativen und die Einbindung von Gesundheitsfachkräften gefördert. Der Vertriebsvertrag zielt darauf ab, die Zugänglichkeit von Wundversorgungs-lösungen in Krankenhäusern, Kliniken und Langzeitpflegeeinrichtungen in ganz Kanada zu verbessern.
Der Präsident und CEO von Kane Biotech, Marc Edwards, hob den doppelten Nutzen der Partnerschaft hervor: den Zugang zu innovativen Wundversorgungs-lösungen zu verbessern und gleichzeitig bedeutende finanzielle Chancen im kanadischen Wundversorgungsmarkt zu nutzen.
- Secured nationwide distribution agreement with Best Buy Medical Canada
- Recently obtained Health Canada regulatory approval for revyve™
- Expansion into the Canadian wound care market presents new revenue opportunities
- None.
Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada
WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel Product line.
In November 2024, Kane Biotech received Health Canada approval for its revyve™ Antimicrobial Wound Gel, marking a significant milestone for the company in advancing wound care solutions. Since then, Kane has been actively working to promote the product and integrate it into the Canadian healthcare system. Through strategic partnerships, educational initiatives, and engagement with healthcare professionals, the company has been focused on demonstrating revyve™’s effectiveness in infection management and wound healing. By increasing awareness and accessibility, Kane aims to establish revyve™ as a trusted solution in hospitals, clinics, and long-term care facilities across Canada.
"This partnership with Best Buy Medical allows us to improve access to innovative wound care solutions for Canadians suffering from chronic, non-healing wounds," said Marc Edwards, President & CEO of Kane Biotech. "By expanding our distribution network, we are not only helping patients and healthcare providers access effective infection management and wound healing solutions, but we are also tapping into a significant financial opportunity in the Canadian wound care market."
"We are excited to partner with Kane Biotech to bring the revyve™ Antimicrobial Wound Gel to the Canadian market," said Jamie Church, CEO of Best Buy Medical. "This collaboration aligns with our mission to offer the highest quality medical products that enhance patient care and outcomes. We believe that revyve™ will be a game-changer in wound care management."
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
About Best Buy Medical Canada
Best Buy Medical Canada is a leading distributor of high-quality medical products, serving healthcare providers, hospitals, clinics, and long-term care facilities across the country. With a strong reputation for reliability and excellence, the company specializes in sourcing and supplying innovative medical solutions that enhance patient care and improve clinical outcomes. Best Buy Medical Canada is committed to supporting the Canadian healthcare system by offering a comprehensive range of products, exceptional customer service, and efficient distribution networks. By partnering with industry leaders, the company ensures that healthcare professionals have access to cutting-edge medical supplies that meet the highest standards of quality and safety.
For more information:
| Marc Edwards | Ray Dupuis | ||||
| Chief Executive Officer | Chief Financial Officer | ||||
| Kane Biotech Inc | Kane Biotech Inc | ||||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | ||||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What is the duration of Kane Biotech's (KNBIF) distribution agreement with Best Buy Medical Canada?
When did Kane Biotech receive Health Canada approval for revyve™ Antimicrobial Wound Gel?
Where will Kane Biotech's revyve™ wound gel be distributed in Canada?
What is the primary purpose of Kane Biotech's revyve™ Antimicrobial Wound Gel?
